Conclusions Overall, the findings show that by 2022, semaglutide had become the predominant GLP-1RA among surveyed US users, likely reflecting its greater weight-management effectiveness reported in earlier research, as well as its 2021 approval for that indication
It is especially recommended when excess weight is associated T2D, polycystic ovary syndrome, MASH, CVD, hypogonadism, musculoskeletal limitations, or as a preoperative intervention before bariatric surgery, and for weight regain after surgery [129]
[1] While the medication does not directly target reproductive hormones, some women have reported menstrual cycle changes after starting treatment
Proven Health Solutions : We combine leading medical treatments like IV drips and weight-loss medications with holistic practices for a complete approach to effective weight management
10.1021/jm9909645 [DOI] [PubMed] [Google Scholar] 43.Agers H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M
A 2022 clinical trial followed about 200 people who had taken semaglutide for more than a year and lost an average of 17 percent of their body weight
